Project Grant R01AI165137
Award Date
11/1/21
Completion Date
4/1/22
Dollars Obligated
$537K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Jupiter, FL 33458, USA
Similar Awards
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $285,816 to The Regents of the University of California, San Francisco (UCSF) to conduct research on modulating ADP-ribosylation as a potential therapeutic target for eliminating latent HIV-1 reservoirs. The overarching goal is to enhance the understanding of ADP-ribosylation's role in HIV-1 biology through...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $234,113 to The University of Texas Southwestern Medical Center to investigate the epigenetic regulation of HIV-1 proviruses and explore novel approaches for eliminating the persistent viral reservoir. The research aims to characterize the role of the H3K9me3 histone modification at the 3' end of integrated HIV-1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $681,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, which runs from July 2024 to May 2026, will fund research to characterize the HIV latent reservoir and model the contributions of antigen-driven and homeostatic proliferation to its persistence in people living with HIV on antiretroviral therapy. The goal is to help design future HIV...
This Project Grant award of $910,905 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by the Scripps Research Institute to develop an HIV vaccine using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This $1,454,724 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to understand the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The primary objectives are to identify key factors, pathways, and regulators that determine the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell lineages, such as microglia and macrophages. The research will...
This federal Project Grant award of $489,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to improve the targeting and elimination of the intact HIV reservoir. The key products of this 2-year project conducted by The Children's Hospital of Philadelphia Research Institute are: Identifying distinct transcriptional, epigenetic, and clonal features of CD4+ T cells with intact...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616.00 to Emory University to develop virus-like particles (VLPs) for an HIV-1 cure strategy. The key objectives are to: Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, paired with AAV vectors expressing broadly neutralizing antibodies to eliminate reactivated HIV-infected cells (the...
The National Institutes of Health (NIH), through the Mental Health Research Grants program (CFDA 93.242) administered by the National Institute of Mental Health (NIMH), has awarded a $434,500 R21 grant to the University of California, San Diego (UCSD) to investigate the epigenetic mechanisms controlling HIV latency and neuropathogenesis in microglia. The project aims to use single-cell multi-omics approaches and state-of-the-art sequencing technologies to characterize the transcriptomic and...
This $459,999 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director (CFDA 93.310 - Trans-NIH Research Support) supports research by the Scripps Research Institute in La Jolla, CA to develop predictive modeling of viral RNA cellular behavior. The key objectives are to: 1) Develop high-throughput technologies that integrate 3D structural ensembles of biomolecules with quantitative measurements of in vitro and cellular functions to build predictive models...